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Abstract
Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT)
is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to
determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement
(BMI) and thus could spare BM biopsy (BMB).
Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially
staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a
positive BMB and/or FDGPET/CT confirmed by targeted biopsy, complementary imaging (CT ormagnetic resonance imaging),
or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy.
Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a
total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative.
For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity
100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and
negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with
confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB
would not have influenced the patient management.
Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG
PET/CT and could therefore be omitted.
Trial registration NCT00554164 and NCT01478542
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Background
Non-Hodgkin lymphoma (NHL) is responsible for about 6%
of all cancer deaths in the western world [1]. Diffuse large B-
cell lymphoma (DLBCL) is the most common subgroup ac-
counting for 30–58% of lymphoma patients [2, 3]. Bone mar-
row involvement (BMI) may influence prognosis and treat-
ment of aggressive B-cell NHL. The addition of the anti-
CD20 antibody rituximab to CHOP polychemotherapy (doxo-
rubicin, cyclophosphamide, vincristine, prednisone) has sig-
nificantly improved the outcome of patients with DLBCL [4,
5]. The International Prognostic Index (IPI) can predict prog-
nosis [6, 7]. An essential part of the IPI is the clinical stage,
and BMI is classified as stage IV [8], indicating a less favor-
able prognosis. The recently published FLYER study demon-
strated that the number of chemotherapy cycles can be re-
duced in patients younger than 60 years with low-risk IPI
[9]. Taken together, the initial determination of the clinical
stage including BMI remains crucial for treatment decisions
and prognosis.
Study results show that, due to its higher sensitivity and
specificity, fluorine-18 fluorodeoxyglucose positron emission
tomography combined with computed tomography (FDG
PET/CT) is superior to computed tomography (CT) alone in
the detection of lymphoma manifestations [10]. It is therefore
recommended for staging [11].
For decades, bone marrow biopsy (BMB) has been the
standard for the evaluation of BMI in lymphoma. Evidence
has been presented that BMI may also be detected by FDG
PET/CT in patients with aggressive B-cell NHL. According to
a recent meta-analysis, FDG PET/CT detects initial BMI with
higher sensitivity than BMB, suggesting that BMB may be
dispensable [12]. The meta-analysis included a total of 654
patients from 7 studies (2 prospective, 3 retrospective, 2 with
unreported design) with up to 133 cases and a maximum of 55
patients in a prospective study [12]. In a pooled estimator, the
sensitivity and specificity of FDG PET/CT for BMI were
88.7% (CI: 82.5–93.3%) and 99.8% (CI: 98.8–100%), respec-
tively [12]. More recent prospective studies with concordant
results addressed the performance of FDG PET/CT compared
to BMB for staging and BMI in mixed populations of 68
patients with FDG-avid lymphoma including 16 DLBCLs
[13] or 35 patients with aggressive NHL, respectively [14].
To the best of our knowledge, there is no large prospective
study on the performance of FDG PET/CT in comparison to
BMB for the detection of BMI in aggressive B-cell NHL.
Our aim was to analyze the diagnostic performance and
relevance of FDG PET/CT for initial staging regarding BMI
in aggressive B-cell NHL using data from two large prospec-
tive randomized multicenter trials of high methodological
quality. We set out to answer the question whether noninva-
sive FDG PET/CT can diagnose BMI more reliably than in-
vasive BMB does, rendering the latter dispensable.
Methods
The present analysis was requested by the German Joint
Federal Committee (Gemeinsamer Bundesauschuss, G-BA),
the highest council of collective self-government of the
German healthcare system under supervision of the German
Federal Ministry of Health. The investigation used the data
from two German prospective phase 3 trials: the PETAL study
(NCT00554164) [15] and the OPTIMAL>60 study
(NCT01478542). The first investigated whether FDG PET/
CT can guide therapy in patients with aggressive NHL,where-
as the second is an ongoing randomized trial including elderly
patients with aggressive B-cell NHL with the purpose of im-
proving outcome and reducing toxicity by using an optimized
schedule of rituximab, substituting conventional by liposomal
vincristine, and PET-guided reduction of therapy. The results
presented here do not represent endpoints of the studies and
have no influence on the endpoints or the conduct of the on-
going OPTIMAL>60 trial. According to the trial protocols,
both a BMB and an FDG PET/CT were performed during
initial staging. Patients were excluded from the analysis if a
diagnosis of aggressive B-cell lymphoma could not be con-
firmed by reference pathology, if BMB or FDG PET/CT were
not done, or if the BMB or imaging data were unavailable for
central review. In order to ensure comparability of the patient
cohorts, only patients with a biopsy-proven, centrally con-
firmed diagnosis of DLBCL, primary mediastinal B-cell lym-
phoma (PMBCL), or follicular lymphoma grade 3b (FL3b)
were included (Fig. 1).
Central reading of PET/CT
All FDG PET/CT images were centrally reviewed for BMI by
an one expert from a panel of nuclear medicine physicians
(DH, JG, KM, FB, KH) with board certifications for CT
(DH, JG, KM) and MRI (DH) who were blinded to the results
of BMB. PET/CT images were obtained as pseudonymized
DICOM data sets from the study centers. PET/CT images
were visualized as reported in the Supplemental Materials.
PET criteria for BMI
The distribution pattern of FDG uptake in BM was rated as
normal, diffusely increased, or unifocal/multifocal. PET pos-
itivity was assessed visually and required an FDG uptake level
above that in normal liver. Diffuse uptake (“uniform increased
FDG uptake throughout the bone marrow space” [16]), with-
out focal uptake, was considered negative for BMI; otherwise,
it was considered positive. Namely, diffuse uptake with con-
current focal uptake and areas of asymmetric diffuse uptake
were considered involved. Foci attributable to physiologic
conditions (e.g., rib fractures or sites of previous BMB) were
considered negative.
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Study-related evaluation of FDG uptake in BM and of
osseous involvement
For semiquantitative assessment in the present analysis, the
intensity of FDG uptake in BM or in BM foci was rated by
a 5-point scale in relation to mediastinal blood pool (MBP)
and liver (1: no uptake, 2: less than or equal to MBP, 3: less
than or equal to the liver, 4: moderately above the liver, 5:
markedly above the liver) [10]. The anatomic localization of
foci in the BM with increased FDG uptake was documented
for further comparison. Osseous involvement was defined by
an affection of the bone detected by CT as a lytic lesion or by
MRI as a bone-invading lesion in cortical bone or in the can-
cellous bone (spongiosa) at the site of FDG uptake. If there
was no anatomic imaging (full-dose CT, low-dose CT, or
MRI) of adequate quality available for comparison in suspi-
cious bone lesions, the presence of bone involvement was
classified as “unknown” for these foci.
Comparison of PET/CT and BMB findings
In a first step, discordant cases of BMB and blinded central
PET/CT reading were identified. Discordant findings were
documented and resolved after unblinding by re-evaluation
in consensus with at least one further panel member and in-
terdisciplinary discussion using findings of complementary
imaging and/or subsequent PET/CT examinations, if avail-
able. In case of an FDG PET/CT result positive for BMI with
negative BMB, all available additional imaging data (mainly
CT or targeted magnetic resonance imaging, MRI) and/or
FDG PET/CT image data sets from restaging or follow-up
examinations were used to determine the final diagnosis of
BMI.
Definition of BM involvement
Based on the published criteria of Berthet and coworkers [17],
a newly defined gold standard was used as reference standard
for BMI. It included a positive BMB, a positive FDG PET/CT
in discordant cases confirmed by targeted biopsy or comple-
mentary CT imaging (if available CT series from PET/CT
were nondiagnostic, e.g., due to limitiations from low-dose
CT protocols), or targeted MRI or concurrent disappearance
of focal FDG PET-avid lesions in the BM together with other
lymphoma manifestations after immunochemotherapy.
Identification of bone marrow infiltration was done using
unilateral iliac crest biopsy. Marrow biopsy specimens were
reported by a reference hematopathologist. The presence of
lymphoma was based on standard immunohistochemistry, in-
cluding antibodies to identify CD3-, CD79a-, and CD20-
positive cells.
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Fig. 1 Consort diagram of
patients from the PETAL and
OPTIMAL>60 trials included in
the bone marrow analysis
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Statistical analysis
To investigate whether the subgroups analyzed in this study
were representative of the total trial populations, characteris-
tics of included and excluded patients were compared using
the chi2, Fisher exact, and Wilcoxon rank sum tests.
Sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated with 95%
confidence intervals (CI) to assess the diagnostic performance
of FDG PET/CT and BMB in relation to the newly defined
gold standard. For the comparison of sensitivities, the
McNemar test was used [18]. Statistical evaluation was per-
formed using SPSS Statistics 25 software (SPSS, Chicago,




From the PETAL and the OPTIMAL>60 trials, subgroups of
660 and 825 patients, respectively, with histopathologically
confirmed aggressive B-cell NHL of the subtypes DLBCL,
PMBCL, and FL3b, were eligible for this pooled analysis. In
433 and 504 cases, both PET/CT images and BMB reports
were available and suitable for analysis in 427 and 503 pa-
tients, respectively (Fig. 1). Characteristics were similar in
patients included and excluded from this analysis
(Supplemental Table 1).
The demographic and clinical characteristics of the analysis
population are shown in Table 1. Overall, both cohorts
(PETAL and OPTIMAL>60) had similar characteristics, ex-
cept for age, which was due to the inclusion criteria of the
trials (the PETAL study included patients 18–80 years of
age; the OPTIMAL>60 study only includes patients aged
61–80 years). The median age of all analyzed patients was
68 years, 56% were male, and 54% had an advanced stage.
According to BMB, 36 of the 427 patients from PETAL (8%)
and 49 of the 503 patients from OPTIMAL>60 (10%) had
BMI; thus, BMB confirmed BMI in 85 of 930 patients in total
(9%). According to initial FDG PET/CT, 88 of the 427 pa-
tients from the PETAL study (21%) and 97 of the 503 patients
from the OPTIMAL>60 study (19%) had BMI, i.e., in total
185 of 930 patients (20%), as shown in Table 1. All 185
patients with BMI diagnosed by FDG PET/CT had an FDG
uptake in the BM at least greater than the intensity of uptake in
normal liver (Table 1), with unifocal, multifocal, or diffusely
increased FDG uptake pattern in 44 (24%), 118 (64%), and 23
(12%) patients, respectively (Table 1). Of these 185 patients,
103 (56%) had concomitant osseous involvement at the site of
the BM lesion; 70 (38%) had no osseous involvement; and in
12 cases (6%), correlative imaging of adequate quality was
not available for central reading so that osseous involvement
was judged “unknown.” In only 50% of the patients were the
FDG-avid BM lesions located at the site commonly used for
BMB (posterolateral iliac crest).
Comparison of initial FDG PET/CT and BMB
Of the 930 patients analyzed, 709 (76%) had a negative base-
line FDG PET/CT and a negative BMB, whereas 49 (5%) had
a positive FDG PET/CT and a positive BMB as demonstrated
in Fig. 2. Thirty-six patients (4%) had a discordant result with
FDG PET/CT negative for BMI but positive BMB. Among
these 36 pat ients , 17 (47%, 3 in PETAL, 14 in
OPTIMAL>60) had an indolent (discordant) NHL in the
BMB, whereas the other 19 patients had an aggressive
(concordant) B-cell lymphoma. One hundred thirty-six pa-
tients (15%) had a discordant result with a positive FDG
PET/CT and a negative BMB (Table 2).
Re-evaluation of discordant findings with imaging
Differences between BMB and FDG PET/CT were further
reviewed by the expert panel. In the OPTIMAL>60 study,
re-evaluation included further imaging (CT, MRI) and FDG
PET/CT follow-up examinations. In 69 of the 74 cases with
positive FDG PET/CT and negative BMB, FDG uptake
completely or partially disappeared in the course of therapy,
compatible with initial BMI. Figure 3 illustrates a typical case.
The 5 remaining patients had no FDG PET/CT follow-up
scans. They had unifocal (n = 2) or multifocal (n = 3) FDG
uptake in the BM with involvement of the humerus, femur,
and digits. According to CT criteria, these lesions were clas-
sified as BMI. Thus, all 74 patients with positive FDG PET/
CT and negative BMB had convincing evidence of true BMI,
which , however , remained undetec ted by BMB
(Supplemental Table 2). The 62 discordant cases of the
PETAL could not be further evalutated, because FDG PET/
CT follow-up scans and/or additional imaging procedures
were not available.
Final diagnosis of BMI
The reference standard for BMI resulted in 709 cases that were
negative, and 221 cases that were positive for BMI, with a
prevalence of BMI of 221/930 = 24%.
Diagnostic performance of BMB for the detection of
BMI
Since 709 of the 845 BMB-negative cases were also neg-
ative according to the reference standard, the NPV of
BMB was 84% (CI: 81–86%) (Table 3). The sensitivity
of BMB was 38% (CI: 32–45%), since 85 of 221 cases
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diagnosed by the reference standard were also identified
by BMB. All 85 BMB-positive cases were also positive
by the reference standard, so the PPV was 100% (CI: 96–
100%). The specificity was also 100% (CI: 99–100%)
(Table 3).
Diagnostic performance of FDG PET/CT for the detec-
tion of BMI
As compared to the reference standard, 185 of 221 cases with
BMI were detected by FDG PET/CT (Table 3), resulting in a







Male 235 (55%) 290 (58%) 525 (56%)
Female 192 (45%) 213 (42%) 405 (44%)
Age, median (range) 61* (18–80) 71 (61–80) 68 (18–80)
Age >60 years 214* (50%) 503 (100%) 717* (77%)
LDH >UNL 247* (58%) 255 (51%) 502* (54%)
ECOG > 1 39* (9%) 23 (5%) 62* (7%)
Stage III/IV 239* (56%) 262 (52%) 501* (54%)
Extralymphatic inv. > 1 130* (31%) 151 (30%) 281* (30%)
IPI 0, 1 166* (39%) 140 (28%) 306* (33%)
IPI 2 98* (23%) 137 (27%) 235* (25%)
IPI 3 98* (23%) 138 (27%) 236* (25%)
IPI 4, 5 64* (15%) 88 (17%) 152* (16%)
Bone marrow involvement by BMB 36 (8%) 49 (10%) 85 (9%)
B-symptoms** 133 (31%) 106 (21%) 239 (26%)
Reference pathology
DLBCL 407 (95%) 489 (97%) 896 (96%)
PMBCL 16 (4%) 4 (1%) 20 (2%)
Follicular lymphoma 3b 4 (1%) 10 (2%) 14 (2%)
Bone marrow involvement by FDG PET/CT 88 (21%) 97 (19%) 185 (20%)
Intensity of FDG uptake
Uptake moderately > liver 4 (4%) 5 (5%) 9 (5%)
Uptake markedly increased > liver 84 (96%) 92 (95%) 176 (95%)
Type of lesion in FDG PET/CT
Unifocal 26 (30%) 18 (19%) 44 (24%)
Multifocal 43 (49%) 75 (77%) 118 (64%)
Diffuse 19 (22%) 4 (4%) 23 (12%)
Skeletal involvement
Osseous involvement 40 (46%) 63 (65%) 103 (56%)
No osseous involvement 38 (43%) 32 (33%) 70 (38%)
Unknown 10 (11%) 2 (2%) 12 (6%)
BM localization in FDG PET/CT
Pelvis (dorsal) or sternum affected 42 (48%) 51 (53%) 93 (50%)
Pelvis (dorsal) and sternum unaffected 44 (50%) 46 (47%) 90 (49%)
Unknown 2 (2%) 0 (0%) 2 (1%)
Bone marrow involvement by reference standard 98 (23%) 123 (24%) 221 (24%)
Abbreviations: BM, bone marrow; BMB, bone marrow biopsy; DLBCL, diffuse large B-cell lymphoma; ECOG,
Eastern Cooperative Oncology Group performance status; FDG PET/CT, fluorine-18 fluorodeoxyglucose posi-
tron emission tomography/computed tomography; IPI, International Prognostic Index; LDH, lactate dehydroge-
nase; PMBCL, primary mediastinal B-cell lymphoma; ULN, upper limit of normal
*One patient with missing values for single IPI factors and IPI score
**9 (PETAL n = 1/OPTIMAL>60 n = 8) unknown values
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sensitivity of 84% (CI: 78–88%). On the other hand, 709 of
the 745 reference standard-negative cases were also found to
be negative by FDG PET/CT, resulting in a NPV of 95% (CI:
93–97%). All 185 PET-positive cases were confirmed to rep-
resent BMI by central review, resulting in a PPV of 100% (CI:
98–100%). Of the 709 PET-negative findings, all were con-
firmed to be negative, so the specificity was 100% (CI: 99–
100%).
The sensitivity of FDG PET/CT was significantly higher
than that of BMB (84% versus 38%; p < 0.001).
Effect of BMI detection on stage
Lactate dehydrogenase (LDH) levels were increased
above the upper limit of normal in 26 of the 36 BMI cases
that were missed by FDG PET/CT. From the remaining
10 patients, one had an ECOG performance status > 1 and
9 were in stage III/IV. Thus, every single patient whose
BMI was missed by FDG PET/CT had another adverse
characteristic according to IPI precluding eligibility for
reduced chemotherapy [9].
On the other side, we observed that in 136 patients with an
FDG PET/CT positive for BMI but negative BMB, a portion
of 80%was already in stage III/IV according to CT-based Ann
Arbor staging. Therefore, 27 patients (BMB negative but
FDG PET/CT positive for BMI) would be upstaged (from
stage I/II to stage III/IV) by FDG PET/CT.
Discussion
The current analysis is derived from a comprehensive data set
which originates from two large prospective randomized mul-
ticenter phase 3 trials. To our knowledge, with 930 analyzed
patients, this is the largest cohort from prospective studies for
the comparison of FDG PET/CT and BMB to detect BMI. In
comparison, Alzahrani et al. analyzed the value of routine
BMB in 530 patients with DLBCL showing no additional
diagnostic or prognostic value of BMB over PET/CT alone.
In contrast to our analysis, their study was retrospective which
may have led to a selection bias [19]. Due to the size and
inclusion criteria of our trials, the risk of a significant selection
bias appeared small. Both the PETAL and the OPTIMAL>60
trials included patients with aggressive B-cell NHL irrespec-
tive of stage or IPI risk group.
Based on BMB, DLBCL involves the BM in up to 27% of
cases [20–22]. The prognostic impact of BMI varies according
to the degree and type (concordant versus discordant) of infil-
tration [22]. In our analysis, the prevalence of BMI detected
by BMB was only 9% (85 of 930 patients), reflecting low
sensitivity (in our analysis only 38%). Our observation is con-
sistent with recently published data [23]. In 74 patients treated
in the OPTIMAL>60 trial, BMB performed on the iliac crest
did not detect BMI, mainly because the involvement was focal
rather than general. Focal involvement has previously been
demonstrated in studies comparing bilateral versus unilateral
BMB [24]. Taking FDG PET/CT and BMB together, 221 of
930 patients showed BMI leading to a prevalence of 24%
which is in line with the observed frequency in other studies
[16, 17, 19, 25, 26]. In our analysis, the PPV for FDG PET/CT
compared to the reference standard was 100% (CI: 98–100%).
Therefore, BMB is dispensable if BMI is detected by FDG
PET/CT. The NPV of FDG PET/CT measured against the
newly defined gold standard was 95% (CI: 93–97%), signifi-
cantly higher than the NPV of BMBwhich was only 84% (CI:
81–86%).
One may ask how many of the patients with diffuse FDG
uptake in BM above that in the liver had BMI.We can analyze
this most accurately by looking at the data from the
OPTIMAL>60 subpopulation where 26 patients exhibited
Fig. 2 Baseline FDG PET (maximumintensity projection in frontal view)
of a male patient with diffuse large B-cell lymphoma. FDG uptake in
bone marrow space (with an intensity markedly above that in the liver)
is diffusely increased without any focus in the bone marrow space apart
from the biopsy site (right iliac crest, outlined arrow), but with
asymmetric uptake (filled arrow) in right and left proximal humerus
(maximum standardized uptake value 7.0 and 3.6, respectively)
consistent with bone marrow involvement as confirmed by bone
marrow biopsy. CT (not shown) revealed no osseous involvement in
the proximal right humerus. Focal uptake in cartilage-bone junctions
(outlined arrow-heads) as foci attributable to benign conditions
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diffuse FDG uptake in BM above that in the liver. In four (1
with moderately and 3 with markedly increased uptake), the
PET pattern of inhomogeneous or asymmetric FDG uptake
into the BM was interpreted (and confirmed) as BMI. PET
was interpreted as negative for BMI in 22 patients with diffuse
FDG uptake in BM (19 moderately and 3 markedly above the
liver) with 6 false-negative cases (all with FDG uptake in BM
only moderately above that in the liver). Thus, 10 of 26 pa-
tients (38%) with diffuse uptake above the liver had BMI (3 of
6 (50%) with markedly increased BM uptake and 7 of 20
(35%) with moderate uptake). Considering all false-negative
BM PET results in the OPTIMAL>60 subpopulation, the pat-
tern of FDG uptake was regarded as normal in 20 patients (1
with uptake less or equal to mediastinal blood pool, 12 with
uptake less or equal to the liver, and 7 cases with FDG uptake
in BM only moderately above that in the liver), while in 6
patients, it was diffusely increased but with a uniform appear-
ance (all only moderately above the level of the liver). In most,
INI RE2
Fig. 3 Female patient with
diffuse large B-cell lymphoma
and multifocal bone marrow
involvement at baseline FDG
PET/CT (INI), which was missed
by bone marrow biopsy and
remitted completely after 6 cycles
of chemoimmunotherapy (RE2).
Maximum-intensity projections
in frontal and lateral view
Table 2 Comparison of the bone
marrow biopsy results, the
baseline FDG PET/CT results,
and the newly defined gold stan-









Negative Negative 329 (77%) 380 (76%) 709 (76%)
Negative Positive 62 (15%) 74 (15%) 136 (15%)
Positive Negative 10 (2%) 26 (5%) 36 (4%)
Positive Positive 26 (6%) 23 (5%) 49 (5%)
BMB Reference standard
Negative Negative 329 (77%) 380 (76%) 709 (76%)
Negative Positive 62 (15%) 74 (15%) 136 (15%)
Positive Negative 0 (0%) 0 (0%) 0 (0%)
Positive Positive 36 (8%) 49 (10%) 85 (9%)
FDG PET/CT Reference standard
Negative Negative 329 (77%) 380 (76%) 709 (76%)
Negative Positive 10 (2%) 26 (5%) 36 (4%)
Positive Negative 0 (0%) 0 (0%) 0 (0%)
Positive Positive 88 (21%) 97 (19%) 185 (20%)
Abbreviations: BMB, bone marrow biopsy; FDG PET/CT, fluorine-18 fluorodeoxyglucose positron emission
tomography/computed tomography
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namely 14 of the 26 patients (54%) with PET false negative
for BMI, BMB reports explicitly contained the information
about the presence of follicular (n = 5) or low-grade lympho-
ma (n = 9) in the BM specimen. These types of NHL are
known on the one hand to potentially transform into aggres-
sive lymphoma and on the other hand to exhibit limited FDG
avidity [27] as a reason why they can be missed by PET.
Our data suggests that BMB can be restricted to a minority of
patients with negative BM findings on PET/CT where detection
of BMI would result in upstaging and a change of therapy. As of
now, this situation is only encountered in young patients (age ≤
60 years) without IPI risk factors or bulky disease in whom
reduced chemotherapy has been shown to be equally effective
as standard treatment [9]. Currently, two trials are testing wheth-
er immunochemotherapy can also be reduced in elderly good-
risk patients (OPTIMAL>60 NCT01478542, LNH 2009-1B
NCT01285765). In other patients, the impact of reduced chemo-
therapy has not yet been evaluated, i.e., they would receive
standard treatment irrespective of the presence or absence of
BMI. Therefore, BMB could be omitted. In our analysis, 26 of
the 36 cases with BMI detected only by BMB had an elevated
LDH, 1 had an ECOG performance status > 1, and 9 were stage
III/IV, demonstrating that, even without a BMB, none of these
cases would have been eligible for reduced chemotherapy. A
BMB may also be discussed in selected other cases, such as
patients in whom prophylactic central nervous system (CNS)–
directed therapy is considered on the basis of the CNS-IPI whose
result is influenced by the presence or absence of BMI [28].
Importantly, BMB is an invasive procedure whereas FDG
PET/CT is noninvasive. Since side effects of BMB or FDG
PET/CT as pre-trial examinations were not recorded in our data
sets, there was no information available about adverse events
resulting from these procedures. But without doubt, a BMB is
more painful than a PET/CT is, and it is associated with the risk
of adverse events such as infection or bleeding [29].
Berthet et al. proposed criteria to confirm BMI in cases
exclusively diagnosed by FDG PET/CT [17]. As compared
to the previous definition, the criteria used here also included
the information obtained from targeted CT imaging (not only
MRI) which is more commonly available than MRI.
The newly defined “gold” standardmay have limitations. The
specificity of FDGPET/CTmay be limited due to potential FDG
uptake in benign bone lesions [30] even though additional full-
dose CT or MRI might help to characterize such lesions.
Nevertheless, PET/CT in our analysis had a specificity of
100% with no false-positive findings. Diagnostic performance
is improved as shown by the clarification of discordant findings
by complementary imaging. We cannot exclude false-negative
findings when both BMB and FDG PET/CT fail to demonstrate
BMI. Whole-body MRI might provide similar sensitivity as
FDG PET/CT for BMI, but this has only been prospectively
evaluated in a limited number of aggressive NHL patients [14].
The prognostic value of BMI as detected by FDG PET/CT
would be of interest. However, outcome data from the
OPTIMAL>60 trial are not yet available, because it is an
ongoing study.
Our analysis has some limitations, as it includes individual
patient data from trials with different inclusion criteria. Most
important are the differences in patient age since
OPTIMAL>60 includes only patients aged 61 years and above.
However, even with different inclusion criteria, no significant
differences were observed between the studies in the incidence
of BMI or other findings underlining the strength of our analysis.
In summary, baseline FDG PET/CT more accurately de-
tects BMI than BMB, with considerably higher sensitivity of
84% versus 38%. By using FDG PET/CT, BMB can be omit-
ted in the vast majority of patients with aggressive NHL. Our
results lend further support to clinical practice guidelines
recommending replacement of BMB by FDG PET/CT in the
initial staging of DLBCL [11, 31].
Table 3 Diagnostic test parameters with 95% confidence intervals of the bone marrow biopsy and baseline FDG PET/CT results in comparison to the







BMB versus reference standard
Sensitivity 36/98 (37%) (27%; 47%) 49/123 (40%) (31%; 49%) 85/221 (38%) (32%; 45%)
Specificity 329/329 (100%) (99%; 100%) 380/380 (100%) (99%; 100%) 709/709 (100%) (99%; 100%)
Positive predictive value 36/36 (100%) (90%; 100%) 49/49 (100%) (93%; 100%) 85/85 (100%) (96%; 100%)
Negative predictive value 329/391 (84%) (80%; 88%) 380/454 (84%) (80%; 87%) 709/845 (84%) (81%; 86%)
FDG PET/CT versus reference standard
Sensitivity 88/98 (90%) (82%; 95%) 97/123 (79%) (71%; 86%) 185/221 (84%) (78%; 88%)
Specificity 329/329 (100%) (99%; 100%) 380/380 (100%) (99%; 100%) 709/709 (100%) (99%; 100%)
Positive predictive value 88/88 (100%) (96%; 100%) 97/97 (100%) (96%; 100%) 185/185 (100%) (98%; 100%)
Negative predictive value 329/339 (97%) (95%; 99%) 380/406 (94%) (91%; 96%) 709/745 (95%) (93%; 97%)
Abbreviations: BMB, bone marrow biopsy; FDG PET/CT, fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography
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